Dressler, Dirk
Altenmüller, Eckart
Giess, Ralf
Krauss, Joachim K.
Adib Saberi, Fereshte
Funding for this research was provided by:
Inge-Diesbach-Stiftung
Article History
Received: 18 May 2022
Revised: 22 July 2022
Accepted: 23 July 2022
First Online: 11 August 2022
Declarations
:
: DD received honoraria for services provided to Allergan, Ipsen, Merz, Lanzhou Institute of Biological Products, Medy-Tox, Revance, Desitin, Syntaxin, AbbVie, Medtronic, St Jude, Boston Scientific, Almirall, Bayer, Sun, Teva, UCB, IAB—Interdisciplinary Working Group for Movement Disorders. He is shareholder of Allergan and holds patents on botulinum toxin and botulinum toxin therapy. FAS is founder and owner of IAB—Interdisciplinary Working Group for Movement Disorders. She received reimbursement from Abbot, AbbVie, Almirall, Allergan, Bayer, Desitin, Dynamed, Hempel GesundheitsPartner, Ipsen, Johnson & Johnson, Licher, Meda, Medtronic, Merz, Orion, PTZ Nawrath, Sensomotorik & Rehabilitation Hellmuth & Thiel, Sintetica, Sporlastic, Sun, Teva, Tricumed, TRS Med, UCB. RG has nothing to disclose. EA has nothing to disclose. JKK is a consultant to Medtronic and to Boston Scientific. His research is supported by Deutsche Forschungsgemeinschaft (Project #201925000).
: The study was performed under the regulations of the local ethical committee of Hannover Medical School.